Evidence map›Paper›PMID 32375888›Full record

ArticleJournal of translational medicine2020

Is HDL cholesterol protective in patients with type 2 diabetes? A retrospective population-based cohort study.

Giovanni Fanni, Rosalba Rosato, Luigi Gentile, Matteo Anselmino, Simone Frea, Valentina Ponzo, Marianna Pellegrini, Fabio Broglio, Francesca Pivari, Gaetano Maria De Ferrari and 2 more

Open access · goldAbstract read
In one paragraph

Article in Journal of translational medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.8field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 3 countries.

Giovanni FanniDepartment of Medical Sciences, University of Turin, Corso AM Dogliotti, 14 10126, Turin, To, Italy.
Rosalba RosatoDepartment of Psychology, University of Turin, Turin, Italy.
Luigi GentileDiabetic Clinic, Hospital of Asti, Asti, Italy.
Matteo AnselminoCardiology Unit, Città della Salute e della Scienza Hospital and University of Turin, Turin, Italy.
Simone FreaCardiology Unit, Città della Salute e della Scienza Hospital and University of Turin, Turin, Italy.
Valentina PonzoDepartment of Medical Sciences, University of Turin, Corso AM Dogliotti, 14 10126, Turin, To, Italy.
Marianna PellegriniDepartment of Medical Sciences, University of Turin, Corso AM Dogliotti, 14 10126, Turin, To, Italy.
Fabio BroglioDepartment of Medical Sciences, University of Turin, Corso AM Dogliotti, 14 10126, Turin, To, Italy.
Francesca PivariDepartment of Health Sciences, University of Milan, Milan, Italy.
Gaetano Maria De FerrariCardiology Unit, Città della Salute e della Scienza Hospital and University of Turin, Turin, Italy.
Ezio GhigoDepartment of Medical Sciences, University of Turin, Corso AM Dogliotti, 14 10126, Turin, To, Italy.
Simona BoDepartment of Medical Sciences, University of Turin, Corso AM Dogliotti, 14 10126, Turin, To, Italy. simona.bo@unito.it.ORCID 0000-0001-6862-8628
University of Turin · ITAzienda Sanitaria Locale di Asti · ITDepartment of Medical Sciences · RUUniversity of Milan · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe protective role of high HDL cholesterol levels against cardiovascular diseases has been recently questioned. Limited data are available on this specific topic in patients with type 2 diabetes mellitus (T2DM). We aimed to evaluate the association of HDL cholesterol concentrations with all-cause and cause-specific mortality in a historical cohort of T2DM patients with 14 years of follow-up.

methodsThis is a retrospective population-based cohort study involving 2113 T2DM patients attending the Diabetic Clinic of Asti. Survival analyses were performed to assess hazard ratios for overall and specific-cause mortality by HDL cholesterol tertiles, using the middle HDL cholesterol tertile as a reference.

resultsThe mean age was 66 ± 11 years; 51.4% of patients had low HDL-cholesterol levels. After a 14-year follow-up, 973/2112 patients had died (46.1%). The HDL cholesterol tertile cut-off points were 37.5 and 47.5 mg/dL (males) and 41.5 and 52.0 mg/dL (females). No associations between lower and upper HDL cholesterol tertiles respectively and all-cause (HR = 1.12; 95% CI 0.96-1.32; HR = 1.11; 0.95-1.30), cardiovascular (HR = 0.97; 0.77-1.23; HR = 0.94; 0.75-1.18) or cancer (HR = 0.92; 0.67-1.25; HR = 0.89; 0.66-1.21) mortality were found. A significantly increased risk for infectious disease death was found both in the lower (HR = 2.62; 1.44-4.74) and the upper HDL-cholesterol tertiles (HR = 2.05; 1.09-3.85) when compared to the reference. Individuals in the upper tertile showed an increased risk for mortality due to diabetes-related causes (HR = 1.87; 1.10-3.15).

conclusionsOur results corroborate the hypothesis that HDL cholesterol levels are nonprotective in T2DM patients. The U-shaped association between HDL-cholesterol levels and mortality associated with infectious diseases should be verified by further studies.

Indexed as

Cardiovascular DiseasesDiabetes Mellitus, Type 2AgedCause of DeathCholesterol, HDLCohort StudiesFemaleHumansMaleMiddle AgedRetrospective StudiesRisk FactorsCholesterol, HDLHigh-density lipoproteinInfectious diseasesMortalityType 2 diabetes mellitus

Identifiers

PMID32375888
PMCPMC7203837
OpenAlexW3022206770

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.